Wende Hutton
InvestorFounderGeneral Partner at Canaan Partners · General Partner, Canaan Partners (Investment Advisory Committee) at Mission Bay Capital · Board director at Qlaris Bio · Board director at Stargazer Pharmaceuticals · Board director at OncoResponse
Menlo Park, California
Writes $250K – $20M checks · typically $10M
About
Wende Hutton is a General Partner at Canaan Partners, where she has invested for over 25 years across medtech, biopharma, and healthcare IT. She began her career at Nellcor (now Medtronic), spent two years in operations at a biotech company, and made biopharma investments at Mayfield Fund before joining Canaan in 2004 as a medtech specialist. She studied human biology and physiology in college and takes a hands-on approach to building teams and strategy at her portfolio companies.
Likely email· guessed from name + firm domain, not firm-published
- w•••@canaan.comreveal100% confident
Invests in
BiotechConsumerDeep TechDigital HealthEnterprise SoftwareFemTechFintechHardwareHealthtechMedical Devices
Board director at Qlaris Bio
Intro paths
In turn, Wende can intro founders to Qlaris Bio's investors below.
Qlaris Bio's investors · 5
Co-founders at Qlaris Bio
Board director at Stargazer Pharmaceuticals
Intro paths
In turn, Wende can intro founders to Stargazer Pharmaceuticals's investors below.
Stargazer Pharmaceuticals's investors · 2
Board director at OncoResponse
Intro paths
In turn, Wende can intro founders to OncoResponse's investors below.
OncoResponse's investors · 7
Experience
- Canaan PartnersGeneral Partnercurrent2004 — present
- Keepyoursightsupporter2013
- Mayfield FundGeneral Partner1993 — 2001
- GenPharm InternationalGeneral Manager, Transgenic Lab Products1991 — 1992
- NellcorDirector, International Business Unit; Dir of Business Development; Marketing1986 — 1990
Education
- Harvard Business School
- Stanford UniversityAB Human Biology
Deals · 12
Qlaris BioBoard seat
via Canaan Partners · filed Jun 2026 · $3.9M raise
OncoResponseBoard seat
via Canaan Partners · filed May 2025
AlcheraBoard seat
via Canaan Partners · filed Nov 2021
HyalexBoard seat
via Canaan Partners · filed Jul 2021 · $34.9M raise
GlookoBoard seat
via Canaan Partners · filed Mar 2021 · $35M raise
Stargazer PharmaceuticalsBoard seat
via Canaan Partners · filed May 2020 · $62.2M raise
Antiva BiosciencesBoard seat
via Canaan Partners · filed Jul 2018 · $15M raise
Revision OpticsBoard seat
via Canaan Partners · filed Nov 2016 · $45M raise
Chrono TherapeuticsBoard seat
via Canaan Partners · filed Sep 2016 · $47.6M raise
Minimally Invasive DevicesBoard seat
via Canaan Partners · filed Nov 2015 · $14.1M raise
Butterfly HealthBoard seat
via Canaan Partners · filed May 2015 · $3.1M raise
Theraclone SciencesBoard seat
via Canaan Partners · filed May 2015 · $4.4M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Transcend Medical
Investor
Alsius CorporationApieronBiPar SciencesCalibra MedicalChimerixDermiraLabrys BiologicsNorthstar NeuroscienceTranscend Medical
Sources: SEC Form D filings · the firm's website.
Colleagues at Canaan Partners
%20copy.jpg)
Frequently asked questions
- Who is Wende Hutton?
- Wende Hutton is a General Partner at Canaan Partners, where she has invested for over 25 years across medtech, biopharma, and healthcare IT. She began her career at Nellcor (now Medtronic), spent two years in operations at a biotech company, and made biopharma investments at Mayfield Fund before joining Canaan in 2004 as a medtech specialist. She studied human biology and physiology in college and takes a hands-on approach to building teams and strategy at her portfolio companies.
- Where does Wende Hutton work?
- Wende Hutton is General Partner at Canaan Partners and Board director at Qlaris Bio and Board director at Stargazer Pharmaceuticals and Board director at OncoResponse.
- What does Wende Hutton invest in?
- Wende Hutton invests in Biotech, Consumer, Deep Tech, Digital Health, Enterprise Software, FemTech, Fintech, Hardware, Healthtech, Medical Devices.
- What check size does Wende Hutton write?
- Wende Hutton typically writes checks of $250K – $20M.
- What boards does Wende Hutton sit on?
- Wende Hutton holds tracked board seats at Alchera, Antiva Biosciences, Antiva Biosciences, Butterfly Health, Chrono Therapeutics, Glooko, Hyalex, Minimally Invasive Devices, OncoResponse, OncoResponse.
- What companies has Wende Hutton invested in?
- Investments tracked here include Alsius Corporation, Antiva Biosciences, Apieron, BiPar Sciences, Calibra Medical, Chimerix, Chrono Therapeutics, Dermira, Glooko, Labrys Biologics, Northstar Neuroscience, Transcend Medical.
- Where did Wende Hutton go to school?
- Wende Hutton studied at Harvard Business School; Stanford University (AB Human Biology).
Same school
Also attended Harvard Business School1,977
+ 1,971 more
Also attended Stanford University2,000
+ 1,994 more
Shared employers
Also worked at Mayfield Fund35
+ 29 more
